TY - JOUR
T1 - The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19
T2 - Systematic Review and Meta-analysis
AU - Klassen, Stephen A.
AU - Senefeld, Jonathon W.
AU - Johnson, Patrick W.
AU - Carter, Rickey E.
AU - Wiggins, Chad C.
AU - Shoham, Shmuel
AU - Grossman, Brenda J.
AU - Henderson, Jeffrey P.
AU - Musser, James
AU - Salazar, Eric
AU - Hartman, William R.
AU - Bouvier, Nicole M.
AU - Liu, Sean T.H.
AU - Pirofski, Liise Anne
AU - Baker, Sarah E.
AU - van Helmond, Noud
AU - Wright, R. Scott
AU - Fairweather, De Lisa
AU - Bruno, Katelyn A.
AU - Wang, Zhen
AU - Paneth, Nigel S.
AU - Casadevall, Arturo
AU - Joyner, Michael J.
N1 - Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/5
Y1 - 2021/5
N2 - To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.
AB - To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85105440274&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.02.008
DO - 10.1016/j.mayocp.2021.02.008
M3 - Review article
C2 - 33958057
AN - SCOPUS:85105440274
SN - 0025-6196
VL - 96
SP - 1262
EP - 1275
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 5
ER -